What is SkinBioTherapeutics plc's (SBTX.L) StockRank?

MoatMap's StockRank for SkinBioTherapeutics plc (SBTX.L) is 21/100, with a Sell signal. This is a composite score combining Quality (43), Value (43), and Momentum (26) factor ranks across MoatMap's 20,000+ stock universe.

Does SkinBioTherapeutics plc have an economic moat?

SkinBioTherapeutics plc (SBTX.L) has a Quality factor score of 43/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is SkinBioTherapeutics plc a buy, hold, or sell?

MoatMap's current signal for SkinBioTherapeutics plc (SBTX.L) is Sell, based on a StockRank of 21/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is SkinBioTherapeutics plc in?

SkinBioTherapeutics plc (SBTX.L) operates in the Healthcare sector, specifically the Biotechnology industry (United Kingdom).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

SBTX.L

SELLREMOVE

SkinBioTherapeutics plc · Healthcare · United Kingdom · $34M · Avg Vol: $70K/d

StockRank

P/E (TTM)

—

ROE

-7.3%

D/E

0.1x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

SkinBioTherapeutics is an early-stage life sciences company focused on skin health. It lacks the proven commercial traction, pricing power, and high ROIC required for our quality compounding lens, making it an inappropriate fit for a concentrated, high-conviction portfolio.

COMPANY DESCRIPTION

SkinBioTherapeutics plc is a life sciences company focused on harnessing the scientific power of the microbiome to develop treatments for skin health. The company's proprietary SkinBiotix platform utilizes lysates derived from probiotic bacteria to improve skin barrier structure and prevent infection. It operates as a commercial-stage niche player, targeting the cosmetic, medical skin care, and infection control markets through strategic licensing agreements.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	100,368	177,289	2M	6M	295.9%
EPS	-0.02	-0.02	-0.02	-0.00	—
Shares	157M	173M	202M	259M	+65.1%
Debt	171,659	135,119	1M	1M	98.1%
Equity	3M	3M	4M	13M	56.1%
Op CF	-4M	-4M	-4M	-2M	—
Inv CF	-129,973	-221,887	-3M	-2M	—
Fin CF	-47,152	3M	6M	9M	—

PRICE (1M)+11182.1%

SMA 50SMA 200

$0.15

RSI (14)

78.8

52W High

$0.31

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

-5.8%38.0

ROE

-7.3%37.1

GP/Assets

26.0%58.7

Op. Margin

-46.5%21.5

FCF/Assets

-11.5%26.3

Piotroski

—7.2

Int. Cover

-6.8x28.4

D/E Ratio

0.12x63.5

Current Ratio

6.14x76.7

Value

P/E (TTM)

—N/A

EV/EBITDA

-27.0x89.4

P/FCF

—N/A

P/B

2.5x47.2

P/S

4.4x44.3

Div Yield

—N/A

Momentum

52W High %

48%21.1

RS 6M

-26%48.6

SMA 50/200

0.37x0.5

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$34M

P/E (Forward)

47.1x

Gross Margin

61.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SBTX.L are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
SBTX.L	SkinBioTherapeutics plc(you)	$34M	21	SELL
IXI.L	IXICO plc	$25M	29	SELL
SAR.L	Sareum Holdings plc	$47M	14	STRONG SELL
HEMO.L	Hemogenyx Pharmaceuticals Plc	$63M	14	STRONG SELL
IMM.L	ImmuPharma plc	$37M	1	STRONG SELL
APTA.L	Aptamer Group PLC	$28M	3	STRONG SELL
POLB.L	Poolbeg Pharma PLC	$56M	39	HOLD
AREC.L	Arecor Therapeutics plc	$34M	59	HOLD
4BB.L	4basebio PLC	$110M	5	STRONG SELL
AUTL	Autolus Therapeutics plc	$471M	22	SELL

Peer medians: ROE 1.2% · P/E 26.9x · Gross margin 50.8%

SkinBioTherapeutics plc (SBTX.L) — Stock Score Summary

SkinBioTherapeutics plc (SBTX.L) has a MoatMap StockRank of 21/100 based on Quality (43/100), Value (43/100), and Momentum (26/100) factor scores. The current signal is SELL. SkinBioTherapeutics is an early-stage life sciences company focused on skin health. It lacks the proven commercial traction, pricing power, and high ROIC required for our quality compounding lens, making it an inappropriate fit for a concentrated, high-conviction portfolio.

Key Financial Metrics

Price	$0.15
Market Cap	$34M
P/E (Forward)	47.09
Price/Book	2.47
Return on Equity	-7.3%
Return on Invested Capital	-5.8%
Debt/Equity	11.77
Gross Margin	61.0%
Operating Margin	-46.5%
Revenue Growth	37.4%
Free Cash Flow	$-3M

SkinBioTherapeutics plc operates in the Biotechnology industry, part of the Healthcare sector (United Kingdom).

Frequently Asked Questions

What is SkinBioTherapeutics plc’s (SBTX.L) StockRank?: MoatMap’s StockRank for SkinBioTherapeutics plc (SBTX.L) is 21/100, with a Sell signal. It is a composite of Quality (43), Value (43), and Momentum (26) factor ranks across MoatMap’s 20,000+ stock universe.
Does SkinBioTherapeutics plc have an economic moat?: SkinBioTherapeutics plc (SBTX.L) has a Quality factor score of 43/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is SkinBioTherapeutics plc a buy, hold, or sell?: MoatMap’s current signal for SkinBioTherapeutics plc (SBTX.L) is Sell, based on a StockRank of 21/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is SkinBioTherapeutics plc in?: SkinBioTherapeutics plc (SBTX.L) operates in the Healthcare sector, specifically the Biotechnology industry (United Kingdom).